Compare WLK & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLK | RDY |
|---|---|---|
| Founded | 1986 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 11.8B |
| IPO Year | 2004 | 2001 |
| Metric | WLK | RDY |
|---|---|---|
| Price | $70.33 | $11.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 1 |
| Target Price | ★ $106.87 | $16.90 |
| AVG Volume (30 Days) | 975.2K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.90% | 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,170,000,000.00 | N/A |
| Revenue This Year | $5.51 | $7.72 |
| Revenue Next Year | $3.74 | $3.50 |
| P/E Ratio | ★ N/A | $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.33 | $11.36 |
| 52 Week High | $124.23 | $15.67 |
| Indicator | WLK | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 24.28 | 32.69 |
| Support Level | $56.33 | $11.36 |
| Resistance Level | $79.57 | $14.08 |
| Average True Range (ATR) | 2.17 | 0.27 |
| MACD | -0.17 | -0.07 |
| Stochastic Oscillator | 9.33 | 28.93 |
Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.